Global Community

TeamViewer’s main business has slowed, but the company still throws off a lot of cash and is trying to restart growth by moving upmarket. The big question is whether its enterprise push—helped by new tools like its AI assistant and augmented reality offering—can outweigh small-business churn, integration headaches, and worries that automation reduces demand for remote support.Read more

Abivax’s lead drug shows strong late-stage results for ulcerative colitis, and the company now has enough cash runway to focus on getting it approved and launched. A simple-to-take treatment and possible interest from a bigger drug company could change how investors see it.Read more

Veeva runs behind-the-scenes software that drugmakers rely on for tightly controlled work, where a mistake can slow a study or paperwork needed to bring medicines to patients. With new AI tools being built right into those existing systems, the big question is whether Veeva can turn that built-in trust into a new wave of growth—without investors overpaying.Read more

Microsoft rarely goes on sale, so it's worth paying attention when the multiple compresses. At around $380, the stock trades at roughly 22–23x trailing earnings and ~14x EV/EBITDA, well below its own seven year historical range.Read more

Lucky Cement’s value case rests on steady day-to-day performance and a history of disciplined spending, which can keep cash coming in over time. The big swing factor is how the future is judged—small changes in expectations about growth and risk can quickly shift what the business looks like it’s worth.Read more

Poland taps Creotech to build homegrown spy satellites, and the company could become a go-to supplier as Europe ramps up small-satellite programs. The catch is that success hinges on big contract wins, flawless launches, and funding new production—any slip could hit hard.Read more

LVMH keeps generating strong cash even as luxury demand cools, but its biggest fashion brands still aren’t clearly picking up again. The key question is whether you should wait for a better buying moment, because a slow recovery could leave today’s price looking merely okay.Read more

Palfinger looks like it’s being priced as if the good part of the cycle is already over, even though its cash generation and debt reduction suggest the business may be on firmer footing than the market assumes. The big question is whether last year’s cash improvement can keep up as demand stays patchy and trade policy and construction weakness remain real risks.Read more

After a rocky early launch, Iovance now has a cancer treatment already cleared for use, and the story shifts from “will it work?” to “can it catch on” as more hospitals come on board and manufacturing improves. If results in other hard-to-treat cancers hold up, the company could grow far beyond melanoma—and it may even draw interest from a bigger drugmaker looking to fill future gaps.Read more